Clinical trial
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly…
NCT00043862 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00043862 |
|---|---|
| Title | The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC) |
| Official title | A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer |
| Acronym | (SCLC) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer, Small Cell, Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | topotecan |
| Enrollment | 60 |
| Start date | Aug 1, 2002 |
| Primary completion | Nov 1, 2005 |
| First posted | Aug 15, 2002 |
| Last update posted | May 31, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: